Clinical Trial Update: A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC [Phase 1, Phase 2]

View source ↗

Summary

This is a multicenter Phase Ib/II trial evaluating Ivonescimab (AK112) in combination with albumin-bound paclitaxel and cisplatin as neoadjuvant therapy for Eso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Abraxane (albumin-bound paclitaxel) (paclitaxel protein-bound albumin)
• CISPLATIN (cisplatin)
• Ivonescimab (AK112) (ivonescimab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Esophageal Squamous Cell Carcinoma, Ivonescimab | Phase 1, Phase 2 | Status: RECRUITING